Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

argenx NV ADR

Healthcare US ARGX

813.14USD
10.97(1.37%)

Last update at 2026-06-03T20:00:00Z

Day Range

793.21814.81
LowHigh

52 Week Range

327.73630.00
LowHigh

Fundamentals

  • Previous Close 802.17
  • Market Cap36536.14M
  • Volume314112
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-150.08450M
  • Revenue TTM1908.66M
  • Revenue Per Share TTM1.28
  • Gross Profit TTM -251.78600M
  • Diluted EPS TTM-0.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -304.49600M -729.31400M -399.74300M -647.80711M -177.22578M
Minority interest - - - - 0.00000M
Net income -295.05300M -709.59400M -408.26500M -651.23490M -182.54884M
Selling general administrative 507.39M 469.92M 307.64M 183.91M 60.32M
Selling and marketing expenses 202.15M 2.21M 59.97M - 12.01M
Gross profit 1108.48M 381.31M -12.76787M -259.07802M -118.64838M
Reconciled depreciation 111.31M 104.34M 5.87M 3.43M 2.17M
Ebit -327.50244M -686.35128M -320.28807M -605.88891M -200.01120M
Ebitda -216.02305M -582.00928M -314.42107M -601.66697M -182.68326M
Depreciation and amortization 111.48M 104.34M 5.87M 4.22M 17.33M
Non operating income net other - - - - 0.00000M
Operating income -425.04900M -719.66300M -348.74600M -514.37686M -200.01120M
Other operating expenses 1651.37M 1130.41M 846.02M 562.36M 279.41M
Interest expense 0.90M 3.91M 1.10M 1.74M 0.14M
Tax provision -9.44300M -19.72000M 8.52M 2.78M 4.75M
Interest income 92.96M 27.66M 3.49M 5.12M 7.87M
Net interest income 92.06M 23.76M -0.94400M -1.41400M 7.75M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -9.44300M -19.72000M 8.52M 3.43M 5.32M
Total revenue 1226.32M 410.75M 497.28M 44.85M 78.17M
Total operating expenses 1533.53M 1100.98M 846.02M 562.36M 279.41M
Cost of revenue 117.83M 29.43M 510.04M 303.93M 196.82M
Total other income expense net 120.55M -5.03746M -35.00782M -127.86952M 22.79M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -295.05300M -709.59400M -408.26500M -528.92300M -162.96500M
Net income applicable to common shares - -709.59400M -408.26500M -528.92300M -162.96500M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4542.46M 3134.26M 2850.27M 2284.87M 1605.59M
Intangible assets 125.23M 174.90M 171.68M 167.78M 44.99M
Earning assets - - - - -
Other current assets 134.07M -0.00100M 58.95M 27.98M 1033.11M
Total liab 444.95M 320.56M 316.05M 606.76M 428.57M
Total stockholder equity 4097.51M 2813.70M 2534.22M 1678.11M 1177.02M
Deferred long term liab - - - - 0.00000M
Other current liab 172.79M 110.14M 88.88M 72.53M 0.39M
Common stock 7.06M 6.64M 6.23M 5.85M 4.79M
Capital stock 7.06M 6.64M 6.23M 5.85M 4.79M
Retained earnings -2404.84400M -2109.79100M -1400.19700M -1059.59239M -372.53338M
Other liab - 9.28M 6.86M 220.59M 218.10M
Good will - - - - 0.00000M
Other assets - 128.45M 119.78M 30.34M 0.00112M
Cash 2048.84M 800.74M 1334.68M 1219.63M 371.09M
Cash and equivalents - - - - -
Total current liabilities 422.99M 302.28M 301.24M 329.26M 179.18M
Current deferred revenue - - - 46.44M 81.03M
Net debt -2028.84400M -788.31400M -1323.21100M -1209.95400M -363.79604M
Short term debt 4.65M 3.42M 3.51M 3.48M 2.21M
Short long term debt - - - - 0.00000M
Short long term debt total 20.00M 12.43M 11.46M 9.68M 7.30M
Other stockholder equity 6423.22M 4309.88M 3462.78M 2531.39M 1465.79M
Property plant equipment - 16.23M 15.84M 9.49M 8.17M
Total current assets 4123.74M 2774.20M 2542.97M 2061.78M 1538.24M
Long term investments 47.16M 40.48M 53.17M 5.14M 2.60M
Net tangible assets - 2638.80M 2362.54M 1227.96M 1010.59M
Short term investments 1131.00M 1391.81M 1002.05M 781.46M 1125.26M
Net receivables 499.27M 277.27M 38.22M 7.46M 31.79M
Long term debt - - - - 0.00000M
Inventory 310.55M 228.35M 109.08M 25.25M -1023.00381M
Accounts payable 245.56M 188.72M 208.85M 206.80M 95.55M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 72.07M 606.97M 465.41M 200.46M 78.97M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - 4.76M 4.28M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 126.45M 49.23M 34.42M 22.24M 0.71M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 418.72M 360.06M 307.30M 223.09M 67.34M
Capital lease obligations 20.00M 12.43M 11.46M 7.87M 6.51M
Long term debt total - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 308.21M -461.18400M -228.23900M 307.64M -744.33800M
Change to liabilities - 0.33M -180.47400M 12.28M 310.63M
Total cashflows from investing activities - -461.18400M -347.07000M 310.25M -744.33800M
Net borrowings - -4.16500M -3.85500M -2.23000M -1.35300M
Total cash from financing activities 1336.73M 843.76M 1121.34M 920.85M 738.60M
Change to operating activities - -34.51400M -44.96500M -22.72800M -10.73000M
Net income -425.04900M -720.34100M -348.74600M -514.37686M -200.01120M
Change in cash 1248.10M -533.93600M 117.87M 813.03M 56.28M
Begin period cash flow 800.74M 1334.68M 1216.80M 407.89M 314.81M
End period cash flow 2048.84M 800.74M 1334.68M 1220.92M 371.09M
Total cash from operating activities -420.32700M -862.80700M -606.81200M -426.44120M 150.76M
Issuance of capital stock 1196.73M 760.95M 1091.33M 899.77M 760.53M
Depreciation 111.31M 104.34M 5.87M 4.22M 2.43M
Other cashflows from investing activities - 13.14M 2.60M 7.06M 5.47M
Dividends paid - 5.47M - - 0.00000M
Change to inventory -83.03000M -119.27700M -83.88000M -25.27996M -28.01479M
Change to account receivables -185.98160M -222.38174M -31.58246M 22.13M -25.70354M
Sale purchase of stock -12.13800M -5.46798M - - 0.00000M
Other cashflows from financing activities 143.80M 86.97M 33.87M 22.39M -20.41402M
Change to netincome - 118.17M 136.54M 190.35M 18.44M
Capital expenditures 43.81M 103.82M 121.43M 5.48M 46.76M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -404.49100M -375.72200M -340.95100M -13.80228M 310.22M
Stock based compensation 232.97M 157.03M 179.37M 97.03M 44.31M
Other non cash items 97.67M -28.11200M -75.00000M -6.49852M -6.18223M
Free cash flow -464.13900M -966.63000M -728.24600M -431.92271M 103.99M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARGX
argenx NV ADR		 10.97 1.37% 813.14 - 103.09 19.14 8.74 18.47 -100.1777
NVO
Novo Nordisk A/S		 2.31 5.51% 44.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 14.76 3.44% 443.10 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.86 1.11% 625.81 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx NV ADR

Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB

Key Executives

Name Title Year Born
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc CEO & Exec. Director 1972
Prof. Hans de Haard Ir, Ph.D. Co-Founder & Chief Scientific Officer 1960
Mr. Karl Gubitz Chief Financial Officer 1970
Mr. R. Keith Woods Chief Operating Officer 1968
Mr. Arjen Lemmen M.Sc. VP of Corp. Devel. & Strategy 1985
Dr. David L. Lacey M.D. Advisor 1952
Ms. Andria Wilk Global Head of Quality 1974
Mr. Filip Borgions VP & Global Head of Technical Operations NA
Ms. Beth DelGiacco VP and Global Head of Corp. Communications & Investor Relations NA
Ms. Malini Moorthy Gen. Counsel 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions